Lessons - Creating and Scaling a Ketamine Company | Jose Muñoz Aycart - Co-Founder of Wondermed
Lessons - Creating and Scaling a Ketamine Company | Jose Muñoz Aycart - Co-Founder of Wondermed
This episode features Jose Muñoz Aycart, co-founder of Wondermed, discussing the journey of building and scaling a ketamine-based treatment company. He shares insights into navigating complex regulations, attracting impact-driven investors, and the unique business model combining technology and personalized treatment in the psychedelic space.
Show Notes
In this "Lessons" episode, we dive into the challenges and triumphs of building Wondermed, a company focused on ketamine-based treatments. Jose Muñoz Aycart, co-founder and managing director, discusses the unique considerations involved in navigating a new and emerging market within the psychedelic space.Building from Scratch: With no existing models, Wondermed meticulously defined legal aspects, business models, and margins. Navigating complex regulations was crucial, taking two years before launch.Investors Driven by Impact: Wondermed attracted investors passionate about ketamine's benefits and those seeking high-growth market innovation. Their unique model combines technology, service, and product, with personalized treatment creating a patient education marketing opportunity.Staged Investment Journey: Fundraising wasn't a one-time event. Wondermed secured capital in stages as the company transitioned from building to growth phases. Transparency throughout the process, including educating investors about the psychedelic space, built trust and addressed regulatory concerns.